A new global study reveals that an immunotherapy drug called teplizumab can delay the onset of Type 1 diabetes for at least two years in high-risk kids and adults, according to the results of a recent study with 28 research sites.
Recently reported in WNDU 16 News Now, reported that the study was led by Benaroya Research Institute at Virginia Mason in Seattle, Washington.
TrialNet recently reported that the Teplizumab Prevention Study is the first to show clinical type I diabetes (T1D) can be delayed for a median of two years in children and adults at high risk. The results were announced June 9, 2019 at the American Diabetes Association’s 79th Annual Scientific Sessions and published in the New England Journal of Medicine.
The global study is great news for the relatives of the millions of people with diabetes who are 15X more likely to succumb to the disease. Of 76 participants in the trial, 72% who got a placebo developed diabetes, compared to only 43% who got Teplizumab. Most of those in the trial were younger than 18.
The News Story
Follow the link to the source for the WNDU 16 News Now coverage of the study and two twins Megan and Madeline Coder—Megan was diagnosed with diabetes at age 9 and her twin Madeline was at high risk. However, Madeline participated in the study and got Teplizumab infusions for 14 days. And she did not get diabetes for two years.
Research Site Comments
Benaroya Research Institute President Dr. Jane Buckner labeled the study “Groundbreaking.” She noted, “This is certainly the first time looking at people at very high risk of getting diabetes who don’t have it that we’ve been able to prove that we could delay disease with this treatment.”
What is Teplizumab?
Known as PRV-031, it is a humanized anti-CD3 monoclonal antibody that is being evaluated for treatment and prevention of type 1 diabetes mellitus (T1DM) made by Prevention Bio. Teplizumab has also been evaluated for treatment of renal allograft rejection, for induction therapy in islet transplant recipients and psoriatic arthritis.
Originally developed at Columbia University, it was then developed by MacroGenics, Inc. in collaboration with Eli Lilly. After some set-backs, the drug was acquired by Prevention Bio.